MX2009003928A - Tratamiento con antiarritmicos y acidos grasos omega-3 y un producto de combinacion de los mismos. - Google Patents

Tratamiento con antiarritmicos y acidos grasos omega-3 y un producto de combinacion de los mismos.

Info

Publication number
MX2009003928A
MX2009003928A MX2009003928A MX2009003928A MX2009003928A MX 2009003928 A MX2009003928 A MX 2009003928A MX 2009003928 A MX2009003928 A MX 2009003928A MX 2009003928 A MX2009003928 A MX 2009003928A MX 2009003928 A MX2009003928 A MX 2009003928A
Authority
MX
Mexico
Prior art keywords
omega
fatty acids
antiarrhythmics
treatment
combination product
Prior art date
Application number
MX2009003928A
Other languages
English (en)
Inventor
Abdel A Fawzy
Ihor Terleckyj
George Bobotas
Roelof M L Rongen
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of MX2009003928A publication Critical patent/MX2009003928A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las combinaciones de uno o más agentes antiarrítmicos con mezclas de ácidos grasos omega-3, métodos de administración de tales combinaciones y dosis de unidad de tales combinaciones.
MX2009003928A 2006-10-13 2007-10-15 Tratamiento con antiarritmicos y acidos grasos omega-3 y un producto de combinacion de los mismos. MX2009003928A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85129406P 2006-10-13 2006-10-13
PCT/US2007/021963 WO2008063323A2 (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof

Publications (1)

Publication Number Publication Date
MX2009003928A true MX2009003928A (es) 2009-09-21

Family

ID=39430253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003928A MX2009003928A (es) 2006-10-13 2007-10-15 Tratamiento con antiarritmicos y acidos grasos omega-3 y un producto de combinacion de los mismos.

Country Status (10)

Country Link
EP (1) EP2083802A2 (es)
JP (1) JP2010506841A (es)
KR (1) KR20090086078A (es)
CN (1) CN101557805A (es)
AU (1) AU2007322291A1 (es)
BR (1) BRPI0719183A2 (es)
CA (1) CA2672876A1 (es)
EA (1) EA200970374A1 (es)
MX (1) MX2009003928A (es)
WO (1) WO2008063323A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
AU2009278317B2 (en) * 2008-08-07 2014-12-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Long-term treatment of symptomatic heart failure
EP3563842A1 (en) * 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2538691C2 (ru) * 2009-04-29 2015-01-10 Амарин Фарма, Инк. Стабильные фармацевтические композиции и способы их применения
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
CN102188417A (zh) * 2010-03-19 2011-09-21 江苏恒瑞医药股份有限公司 决奈达隆药物组合物
FR2967067A1 (fr) 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
WO2013040507A1 (en) * 2011-09-15 2013-03-21 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
WO2013116738A1 (en) * 2012-02-03 2013-08-08 Cardeus Pharmaceuticals, Inc. Drug formulations
WO2013176455A1 (ko) 2012-05-22 2013-11-28 건일제약 주식회사 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
WO2017083397A1 (en) * 2015-11-09 2017-05-18 Cayo Max A Cardiac glycosides for the treatment of hypercholesterolemia
US20190054184A1 (en) * 2016-02-12 2019-02-21 The General Hospital Corporation Targeting Macrophages to Modulate Electrical Conduction in the Heart
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
WO2019204326A1 (en) * 2018-04-16 2019-10-24 Alsar Ltd Partnership Compositions and methods for sustained release of flecainide
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2893866B2 (ja) * 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
GB0120415D0 (en) * 2001-08-22 2001-10-17 Isis Innovation Palatable high fat composition
ITMI20020731A1 (it) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3

Also Published As

Publication number Publication date
WO2008063323A2 (en) 2008-05-29
EP2083802A2 (en) 2009-08-05
KR20090086078A (ko) 2009-08-10
JP2010506841A (ja) 2010-03-04
WO2008063323A3 (en) 2008-12-31
CN101557805A (zh) 2009-10-14
AU2007322291A1 (en) 2008-05-29
CA2672876A1 (en) 2008-05-29
EA200970374A1 (ru) 2009-10-30
BRPI0719183A2 (pt) 2014-06-03

Similar Documents

Publication Publication Date Title
MX2009003928A (es) Tratamiento con antiarritmicos y acidos grasos omega-3 y un producto de combinacion de los mismos.
MX2008000915A (es) Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
WO2007016256A3 (en) Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
CA118472S (en) Wall-mountable lighting control unit
CA118470S (en) Wall-mountable lighting control unit
CA118468S (en) Wall-mountable lighting control unit
CA118471S (en) Wall-mountable lighting control unit
CA118469S (en) Wall-mountable lighting control unit
CA118467S (en) Wall-mountable lighting control unit
CA118466S (en) Wall-mountable lighting control unit
CA118473S (en) Wall-mountable lighting control unit
CA118465S (en) Wall-mountable lighting control unit
AU319601S (en) Bottle
TW200716119A (en) A solid pharmaceutical dosage formulation
MY147247A (en) Organic compounds and their uses
PA8631801A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
TW200626134A (en) Treatment of IgA nephropathy with Omega-3 fatty acids
UA98299C2 (ru) Новая лекарственная форма рацекадотрила
AU317487S (en) A plunger
CA125219S (en) Handle for pullup exercise bar
MX2008011454A (es) Uso novedoso de agentes antihistaminicos para el tratamiento preventivo o temprano de sindromes inflamatorios, en particular los que son accionados por togavirus.
AU313504S (en) Product packaging
AU302434S (en) Vibroheat capsule I
AR067351A1 (es) Combinacion de picotamida con nafronil
CL2007002981A1 (es) Composicion farmaceutica que contiene 75 mg del isomero dextrogiro de clopidogrel y 300 mg de triflusal, util en el tratamiento de enfermedades tromboembolicas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal